Immix Biopharma (NASDAQ:IMMX) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Immix Biopharma (NASDAQ:IMMX) released its quarterly earnings results on Tuesday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08), Zacks reports.

Immix Biopharma Stock Up 3.8 %

Immix Biopharma stock traded up $0.06 during midday trading on Thursday, reaching $1.63. The stock had a trading volume of 7,957 shares, compared to its average volume of 177,373. The company has a fifty day moving average of $1.66 and a 200 day moving average of $1.97. Immix Biopharma has a 52-week low of $1.26 and a 52-week high of $7.75. The firm has a market cap of $44.74 million, a price-to-earnings ratio of -1.90 and a beta of 0.11.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a report on Thursday, October 3rd.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.